MEX3A knockdown inhibits the tumorigenesis of colorectal cancer via modulating CDK2 expression

xlomafota13 shared this article with you from Inoreader MEX3A knockdown inhibits the tumorigenesis of colorectal cancer via modulating CDK2 expression Via Experimental and therapeutic medicine Exp Ther Med. 2021 Nov;22(5):1343. doi: 10.3892/etm.2021.10778. Epub 2021 Sep 22. ABSTRACT Colorectal cancer (CRC) is a malignant tumor of the gastrointestinal tract and a leading cause of cancer-associated mortality worldwide. Mex-3 RNA binding family member A (MEX3A) promotes the progression of multiple types of cancer, including ovarian and cervical cancer. However, to the best of our knowledge, the role of MEX3A in CRC is not completely understood. Therefore, the present study aimed to investigate the function of MEX3A in CRC. The mRNA and protein expression levels of MEX3A in CRC cells were analyzed using reverse transcription-quantitative PCR and western blotting, respectively. Cell Counting Kit-8 assays were used to measure cell viability. Cell apoptosis and cell cycle distribution were detected via flow cytometry, and CRC cell invasion was analyzed by performing Transwell assays. Moreover, the mitochondrial membrane potential i n CRC cells was measured via JC-1 staining. The results of the present study revealed that the expression levels of MEX3A were upregulated in CRC tissues compared with adjacent healthy tissues. MEX3A knockdown notably inhibited CRC cell viability, and induced apoptosis and mitochondrial injury. In addition, MEX3A knockdown markedly induced G1 phase cell cycle arrest in CRC cells via downregulating CDK2 expression. In conclusion, the findings of the present study suggested that MEX3A knockdown may inhibit the tumorigenesis of CRC cells by regulating CDK2 expression. Therefore, MEX3A may serve as a novel target for CRC treatment. PMID:34630697 | PMC:PMC8495542 | DOI:10.3892/etm.2021.10778 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.